SAFETY AND TOLERABILITY OF CONVERSION TO SIPONIMOD WITH AND WITHOUT TITRATION IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS: INTERIM RESULTS OF THE PHASE 3B EXCHANGE STUDY

Authors
Category Primary study
JournalBMJ Neurology Open
Year 2022
This article has no abstract
Epistemonikos ID: 42b60550e18ec096f37b5feada171dd95d4973bc
First added on: Feb 17, 2025